Abstract: The present invention relates to a method for determining the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor cells or stem cells based on their released TGF-9 levels in culture. The present invention also relates to isolated populations of mesenchymal lineage precursor cells or stem cells selected based on the level of TGF-9 levels released by such cells in culture. The present invention further relates to treatment of a subject suffering from a degenerative disc disease by administering such selected cell populations.

Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.

Abstract: The present disclosure relates to methods for treating or preventing heart failure in subjects with elevated left ventricular end systolic volume (LVESV). In particular, the present disclosure related to methods for treating or preventing heart failure in subjects with a LVESV of greater than 70 ml (>70 ml).

Abstract: The present invention relates to a method for determining the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor cells or stem cells based on their released TGF-9 levels in culture. The present invention also relates to isolated populations of mesenchymal lineage precursor cells or stem cells selected based on the level of TGF-9 levels released by such cells in culture. The present invention further relates to treatment of a subject suffering from a degenerative disc disease by administering such selected cell populations.

Abstract: The present disclosure relates to methods for treating or preventing heart failure in subjects with elevated left ventricular end systolic volume (LVESV). In particular, the present disclosure relates to methods for treating or preventing heart failure in subjects with a LVESV of greater than 70 ml (>70 ml).

Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

Abstract: The present disclosure relates to methods, cell culture medium and compositions that promote cell proliferation during fetal bovine serum free cell culture.

Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.

Abstract: The present disclosure relates to methods for preventing progressive heart failure in subjects with persistent left ventricular (LV) dysfunction. Such methods may also be used for treating or preventing progressive heart failure in subjects with a proximal left anterior descending (LAD) lesion and persistent left ventricular dysfunction.

Abstract: The disclosure provides stem cells which express high levels of Angeopoetin-1 (Ang1) and methods for their production. Such stem cells may be used in a range of therapeutic applications.

Abstract: The present disclosure relates to methods for preventing progressive heart failure in subjects with persistent left ventricular (LV) dysfunction. Such methods may also be used for treating or preventing progressive heart failure in subjects with a proximal left anterior descending (LAD) lesion and persistent left ventricular dysfunction.

Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.

Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.

Abstract: The disclosure provides stem cells which express high levels of Angeopoetin-1 (Ang1) and methods for their production. Such stem cells may be used in a range of therapeutic applications.

Abstract: An apparatus for separating cells from microcarriers comprises a chamber having a body and a base. The chamber is configured to receive a mixture comprising cells and microcarriers. The apparatus further comprises a filtration element disposed within the chamber and coupled to the body. The filtration element is configured to filter microcarriers from the mixture. The apparatus further comprises an adjustment mechanism coupled to the chamber. The adjustment mechanism is configured for selective extension and retraction of at least a portion of the body of the chamber to move the filtration element relative to the base of the chamber.

Abstract: The present disclosure relates to methods and compositions for expansion of human hematopoietic stem cells. The present disclosure also relates to methods of treatment involving the use of the expanded HSCs.

Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.

Abstract: The present disclosure relates to cellular compositions that are modified to introduce a nucleic acid or vector expressing the same. Such compositions may be used to deliver nucleic acid to a target cell and treat disease such as cancer.

Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.

Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.